Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05559866 · ClinicalTrials.gov registry record · NA

Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Trial

A NA study of Obesity, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT05559866: Completed NA study of Obesity, sponsored by Mayo Clinic.

NCT05559866 is a NA study of Obesity that has completed, run by Mayo Clinic. The registered enrollment target is 45 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05559866, a NA study of Obesity, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

This study is being done to evaluate the safety and effectiveness of combined Hybrid Argon Plasma Coagulation (HAPC) and Endoscopic Sleeve Gastroplasty (ESG) for weight loss and improvement in obesity-related co-morbidities compared to ESG alone in participants with a BMI ≥ 30 and ≤40 kg/m² who have failed to achieve and maintain weight loss with a non-surgical program.

Primary Outcome

The primary outcomes are durability of plications and endoscopic sutures on repeat endoscopy at 6 months, in the two randomized arms. Endoscopic scale runs from 0 to 3. A lower score indicates less durability and a higher score indicates greater durability.

Conditions Studied

Obesity

Interventions

  • DEVICE Apollo ESG
  • DEVICE Apollo ESG with ERBE HAPC

Study Locations (1)

Minnesota

  • Mayo Clinic Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2022-11-18
Est. Completion 2025-01-17
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT05559866 record still lists

NCT05559866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Apollo ESG is the first listed.

NCT05559866 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05559866 about?

NCT05559866 is a clinical study titled "Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Trial". This study is being done to evaluate the safety and effectiveness of combined Hybrid Argon Plasma Coagulation (HAPC) and Endoscopic Sleeve Gastroplasty (ESG) for weight loss and improvement in obesity-related co-morbidities compared to ESG alone in participants with a BMI ≥ 30 and ≤40 kg/m² who have...

What is the current status of trial NCT05559866?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2022-11-18. Estimated completion is 2025-01-17.

What conditions does trial NCT05559866 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT05559866?

The interventions under investigation include: Apollo ESG (DEVICE), Apollo ESG with ERBE HAPC (DEVICE).

Who is sponsoring clinical trial NCT05559866?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05559866 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05559866's enrollment target sits among peer trials

45 752nd of 1053 higher than 295 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05559866, the US trial registry maintained by the National Library of Medicine. NCT05559866 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.